Showing results (241-250 of 267) with videos related to

Sort By:
Pageof 27
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2000
The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patientsJ Klastersky, M Paesmans, E B Rubenstein, et al.
Lung Cancer (Amsterdam, Netherlands)|December 1, 1994
A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5 fluorouracile: a regimen associated with major toxicity in patients with advanced non-small cell lung cancerJ Klastersky, J P Sculier, F Ries, et al.
Lung Cancer (Amsterdam, Netherlands)|June 12, 2002
A phase II study testing paclitaxel as second-line single agent treatment for patients with advanced non-small cell lung cancer failing after a first-line chemotherapyJ P Sculier, T Berghmans, J J Lafitte, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1994
A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5-fluorouracil. A regimen associated with major toxicity in patients with advanced non-small lung cancer. European Lung Cancer Working PartyJ Klastersky, J P Sculier, F Ries, et al.
European Journal of Cancer (Oxford, England : 1990)|June 9, 1998
Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working PartyM Paesmans, J P Sculier, P Libert, et al.
International Journal of Oncology|May 10, 2011
A phase-ii study testing a combination chemotherapy with epirubicin and vindesine as 2nd line treatment for patients with advanced non-small-cell lung-cancerJ Sculier, G Bureau, J Thiriaux, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2002
A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancerJ P Sculier, J J Lafitte, J Lecomte, et al.
Antimicrobial Agents and Chemotherapy|January 1, 1986
Clinical evaluation of teicoplanin for therapy of severe infections caused by gram-positive bacteriaY Glupczynski, H Lagast, P Van der Auwera, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 28, 2006
Factors that influence cancer patients' anxiety following a medical consultation: impact of a communication skills training programme for physiciansA Liénard, I Merckaert, Y Libert, et al.
Cancer|August 10, 2000
Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 yearsM Paesmans, J P Sculier, J Lecomte, et al.
Pageof 27